138 related articles for article (PubMed ID: 18977464)
1. Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude.
Seheult RD; Ruh K; Foster GP; Anholm JD
Respir Physiol Neurobiol; 2009 Feb; 165(2-3):123-30. PubMed ID: 18977464
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema.
Fischler M; Maggiorini M; Dorschner L; Debrunner J; Bernheim A; Kiencke S; Mairbäurl H; Bloch KE; Naeije R; Brunner-La Rocca HP
Am J Respir Crit Care Med; 2009 Aug; 180(4):346-52. PubMed ID: 19520908
[TBL] [Abstract][Full Text] [Related]
3. Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans.
Pham I; Wuerzner G; Richalet JP; Peyrard S; Azizi M
Eur J Clin Invest; 2010 Mar; 40(3):195-202. PubMed ID: 20415698
[TBL] [Abstract][Full Text] [Related]
4. Exhaled nitric oxide and pulmonary artery pressures during graded ascent to high altitude.
Donnelly J; Cowan DC; Yeoman DJ; Lucas SJ; Herbison GP; Thomas KN; Ainslie PN; Taylor DR
Respir Physiol Neurobiol; 2011 Aug; 177(3):213-7. PubMed ID: 21515414
[TBL] [Abstract][Full Text] [Related]
5. Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study.
Modesti PA; Vanni S; Morabito M; Modesti A; Marchetta M; Gamberi T; Sofi F; Savia G; Mancia G; Gensini GF; Parati G
Circulation; 2006 Sep; 114(13):1410-6. PubMed ID: 16982943
[TBL] [Abstract][Full Text] [Related]
6. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
[TBL] [Abstract][Full Text] [Related]
7. Identification of individuals susceptible to high-altitude pulmonary oedema at low altitude.
Dehnert C; Grünig E; Mereles D; von Lennep N; Bärtsch P
Eur Respir J; 2005 Mar; 25(3):545-51. PubMed ID: 15738301
[TBL] [Abstract][Full Text] [Related]
8. Prevention of high-altitude pulmonary edema by nifedipine.
Bärtsch P; Maggiorini M; Ritter M; Noti C; Vock P; Oelz O
N Engl J Med; 1991 Oct; 325(18):1284-9. PubMed ID: 1922223
[TBL] [Abstract][Full Text] [Related]
9. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans.
Basnyat B; Hargrove J; Holck PS; Srivastav S; Alekh K; Ghimire LV; Pandey K; Griffiths A; Shankar R; Kaul K; Paudyal A; Stasiuk D; Basnyat R; Davis C; Southard A; Robinson C; Shandley T; Johnson DW; Zafren K; Williams S; Weiss EA; Farrar JJ; Swenson ER
High Alt Med Biol; 2008; 9(3):209-16. PubMed ID: 18800957
[TBL] [Abstract][Full Text] [Related]
10. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
[TBL] [Abstract][Full Text] [Related]
12. Ischemic preconditioning improves oxygen saturation and attenuates hypoxic pulmonary vasoconstriction at high altitude.
Foster GP; Giri PC; Rogers DM; Larson SR; Anholm JD
High Alt Med Biol; 2014 Jun; 15(2):155-61. PubMed ID: 24949710
[TBL] [Abstract][Full Text] [Related]
13. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
[TBL] [Abstract][Full Text] [Related]
14. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study.
Hebert A; Mikkelsen UR; Thilen U; Idorn L; Jensen AS; Nagy E; Hanseus K; Sørensen KE; Søndergaard L
Circulation; 2014 Dec; 130(23):2021-30. PubMed ID: 25446057
[TBL] [Abstract][Full Text] [Related]
15. Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia.
Faoro V; Boldingh S; Moreels M; Martinez S; Lamotte M; Unger P; Brimioulle S; Huez S; Naeije R
Chest; 2009 May; 135(5):1215-1222. PubMed ID: 19188550
[TBL] [Abstract][Full Text] [Related]
16. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis.
Berger RM; Beghetti M; Galiè N; Gatzoulis MA; Granton J; Lauer A; Chiossi E; Landzberg M
Int J Cardiol; 2010 Oct; 144(3):373-8. PubMed ID: 19464064
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.
Iversen K; Jensen AS; Jensen TV; Vejlstrup NG; Søndergaard L
Eur Heart J; 2010 May; 31(9):1124-31. PubMed ID: 20202971
[TBL] [Abstract][Full Text] [Related]
18. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
[TBL] [Abstract][Full Text] [Related]
19. Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudes.
Faoro V; Huez S; Giltaire S; Pavelescu A; van Osta A; Moraine JJ; Guenard H; Martinot JB; Naeije R
J Appl Physiol (1985); 2007 Oct; 103(4):1161-5. PubMed ID: 17615281
[TBL] [Abstract][Full Text] [Related]
20. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
